Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab

Transplantation

Volumn 97, Issue 7, 2014, Pages 755-761

  Barbosa, Debora ^a   Kahwaji, Joseph ^a   Puliyanda, Dechu ^a   Mirocha, James ^a   Reinsmoen, Nancy ^a   Lai, Chih Hung ^a   Villicana, Rafael ^a   Peng, Alice ^a   Jordan, Stanley C ^a   Vo, Ashley ^a   Toyoda, Mieko ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibodies; BK virus; Desensitization; Infection; Rejection; Rituximab

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; CYCLOSPORIN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BK VIRUS INFECTION; CELL COUNT; CHRONIC ALLOGRAFT NEPHROPATHY; COHORT ANALYSIS; CONTROLLED STUDY; DESENSITIZATION; DISEASE FREE SURVIVAL; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HLA TYPING; HUMAN; IMMUNOSURVEILLANCE; INCIDENCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BK VIRUS; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RISK FACTORS; VIREMIA;

EID: 84897500954     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437671.78716.f3     Document Type: Article

References (20)

1. Wiseman A. Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis 2009; 54: 131.
2. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3: 611.
3. Hirsch HH, Randhawa P, Practice AIDCo. BK virus in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S136.
4. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019.
5. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
6. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
7. Kahwaji J, Vo AA, Jordan SC. ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation? Expert Rev Clin Immunol 2010; 6: 893.
8. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. NEngl JMed 2011; 365: 318.
9. Kahwaji J, Toyoda M, Reinsmoen N, et al. Infectious complications associated with rituximab for desensitization protocols. Am J Transplant 2010; 10: 170.
10. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997; 9: 396.
11. Takagi T, Ishida H, Shirakawa H, et al. Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. Transpl Immunol 2010; 23: 220.
12. Pescovitz MD, Torgerson TR, Ochs HD, et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011; 128: 1295.
13. Takagi T, Ishida H, Shirakawa H, et al. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010; 89: 1466.
14. Genberg H, Kumlien G, Wennberg L, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85: 1745.
15. Schachtner T, Müller K, Stein M, et al. BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant 2011; 11: 2443.
16. Theodoropoulos N, Wang E, Penugonda S, et al. BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation. Am J Transplant 2013; 13: 197.
17. Hirsch HH, Vincenti F, Friman S, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 2013; 13: 136.
18. Johnston O, Jaswal D, Gill JS, et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010; 89: 1057.
19. Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus- associated nephropathy. Am J Transplant 2010; 10: 2615.
20. Anyaegbu EI, Almond PS, Milligan T, et al. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant 2012; 16: E19.